Prevalence of cancer-related fatigue based on severity: a systematic review and meta-analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
received:
23
03
2023
accepted:
19
07
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Cancer-related fatigue (CRF) affects therapeutic compliance and clinical outcomes including recurrence and mortality. This study aimed to comprehensively and comparatively assess the severity-based prevalence of CRF. From two public databases (PubMed and Cochrane Library), we extracted data containing information on both prevalence and severity of fatigue in cancer patients through December 2021. We conducted a meta-analysis to produce point estimates using random effects models. Subgroup analyses were used to assess the prevalence and severity by the organ/system tumor development, treatment phase, therapeutic type, sex and assessment method. A total of 151 data (57 studies, 34,310 participants, 11,805 males and 22,505 females) were selected, which indicated 43.0% (95% CI 39.2-47.2) of fatigue prevalence. The total CRF prevalence including 'mild' level of fatigue was 70.7% (95% CI 60.6-83.3 from 37 data). The prevalence of 'severe' fatigue significantly varied by organ/system types of cancer origin (highest in brain tumors 39.7% vs. lowest in gynecologic tumors 3.9%) and treatment phase likely 15.9% (95% CI 8.1-31.3) before treatment, 33.8% (95% CI 27.7-41.2) ongoing treatment, and 24.1% (95% CI 18.6-31.2) after treatment. Chemotherapy (33.1%) induced approximately 1.5-fold higher prevalence for 'severe' CRF than surgery (22.0%) and radiotherapy (24.2%). The self-reported data for 'severe' CRF was 20-fold higher than those assessed by physicians (23.6% vs. 1.6%). Female patients exhibited a 1.4-fold higher prevalence of 'severe' fatigue compared to males. The present data showed quantitative feature of the prevalence and severity of CRF based on the cancer- or treatment-related factors, sex, and perspective of patient versus physician. In the context of the medical impact of CRF, our results provide a comparative reference to oncologists or health care providers making patient-specific decision.
Identifiants
pubmed: 37550326
doi: 10.1038/s41598-023-39046-0
pii: 10.1038/s41598-023-39046-0
pmc: PMC10406927
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12815Informations de copyright
© 2023. Springer Nature Limited.
Références
J Clin Oncol. 2014 Jun 20;32(18):1882-8
pubmed: 24778393
Cancer. 2014 Feb 1;120(3):425-32
pubmed: 24436136
J Pain Symptom Manage. 2011 Feb;41(2):426-35
pubmed: 21216563
Gynecol Oncol. 2015 Mar;136(3):446-52
pubmed: 25458588
Kidney Int. 2014 Sep;86(3):497-505
pubmed: 24694985
Brain Behav Immun. 2016 Feb;52:98-105
pubmed: 26456694
Clin Cancer Res. 2006 May 1;12(9):2759-66
pubmed: 16675568
Support Care Cancer. 2019 Aug;27(8):2809-2818
pubmed: 30539313
Inflamm Bowel Dis. 2011 Jul;17(7):1564-72
pubmed: 21674713
Sci Rep. 2021 Oct 25;11(1):20977
pubmed: 34697347
JAMA Oncol. 2017 Jul 01;3(7):961-968
pubmed: 28253393
Cancer Med. 2019 May;8(5):2535-2544
pubmed: 30864301
Oncotarget. 2018 Jul 27;9(58):31244-31252
pubmed: 30131851
J Clin Oncol. 2016 Dec 20;34(36):4329-4337
pubmed: 27998235
J Transl Med. 2020 Feb 24;18(1):100
pubmed: 32093722
Int J Nurs Stud. 2020 Nov;111:103707
pubmed: 32920423
J Clin Med. 2020 Oct 28;9(11):
pubmed: 33126460
Ann Oncol. 2004 Jun;15(6):896-905
pubmed: 15151946
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Cancer. 2002 Jan 15;94(2):528-38
pubmed: 11900238
Ann Oncol. 2007 Nov;18(11):1861-9
pubmed: 17804467
J Pain Symptom Manage. 2008 Jun;35(6):644-55
pubmed: 18358687
J Clin Oncol. 2003 Apr 1;21(7):1249-54
pubmed: 12663711
Health Qual Life Outcomes. 2008 Nov 14;6:100
pubmed: 19014588
Support Care Cancer. 2008 Apr;16(4):379-86
pubmed: 17724621
CA Cancer J Clin. 2020 Sep;70(5):375-403
pubmed: 32683683
J Clin Oncol. 2014 Feb 20;32(6):557-63
pubmed: 24419112
Eur J Cancer. 2018 Sep;101:47-54
pubmed: 30014974
Support Care Cancer. 2018 Oct;26(10):3353-3364
pubmed: 29961146
Am J Hosp Palliat Care. 2011 Aug;28(5):350-5
pubmed: 21148160
Cancer Res. 2018 Feb 1;78(3):695-705
pubmed: 29217760
Eur J Cancer. 2001 Jul;37(11):1385-93
pubmed: 11435069
Parkinsonism Relat Disord. 2015 Sep;21(9):1093-5
pubmed: 26228083
Brain Behav Immun. 2020 Aug;88:230-241
pubmed: 32428555
Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70
pubmed: 23139054
J Pain Symptom Manage. 2021 Jan;61(1):167-189.e14
pubmed: 32768552
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
pubmed: 15173079
Neurology. 2011 Mar 15;76(11):953-9
pubmed: 21403106
Clin Cancer Res. 2009 Sep 1;15(17):5534-40
pubmed: 19706826
Curr Treat Options Oncol. 2020 Feb 5;21(2):17
pubmed: 32025928
J Pain Symptom Manage. 2002 Nov;24(5):481-93
pubmed: 12547048
Psychosom Med. 2014 Sep;76(7):519-28
pubmed: 25186656
J Clin Oncol. 2014 Jun 10;32(17):1840-50
pubmed: 24733803
Cancer Med. 2018 Sep;7(9):4396-4405
pubmed: 30088335
BMC Public Health. 2017 Aug 14;17(1):654
pubmed: 28806984
BMC Public Health. 2013 Feb 19;13:154
pubmed: 23421987
Ann Oncol. 2019 Dec 1;30(12):1914-1924
pubmed: 31613312
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247
Psychol Bull. 2008 Jan;134(1):1-30
pubmed: 18193993
Ann Hematol. 2018 Nov;97(11):2235-2243
pubmed: 30054708
Cancer Res. 2009 Jun 1;69(11):4700-7
pubmed: 19470769
Cancer. 2005 Oct 15;104(8):1772-8
pubmed: 16116608
J Clin Oncol. 2013 Sep 1;31(25):3076-82
pubmed: 23897970